StageZero Life Sciences Ltd. (SZLS.TO)

0.0400 0.0000 (0.00%) At close: 03:46PM EDT

StageZero Life Sciences Ltd.

70 East Beaver Creek Road
Unit 30
Richmond Hill, ON L4B 3B2
Canada

https://www.stagezerolifesciences.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 40

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. James R. Howard-Tripp	Executive Chairman & CEO	368.88k	N/A	N/A
Dr. Choong-Chin Liew Ph.D.	Co-Founder	100k	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

Corporate Governance

StageZero Life Sciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.